AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32984901 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid clinical decision support system (machine learning and rule-based expert system)
Number of subjects: 10716
Study 32984901 — intervention group
Group type: COMPARATOR
Intervention: Computerized alerts generated by a clinical decision support (CDS) system
Number of subjects: 10716
Study 32984901 — intervention group
Group type: COMPARATOR
Intervention: Literature-based multicriteria query prioritization technique
Number of subjects: 10716
Study 36241145 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study 36241145 — intervention group
Group type: COMPARATOR
Intervention: Education (UC + educational materials about cervical cancer screening)
Number of subjects: 0
Study 36241145 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-Mail (UC + Education + a mailed self-sampling kit)
Number of subjects: 0
Study 36241145 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-In (UC + Education + option to request a kit)
Number of subjects: 0
Study 34844191 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation plasma protein profiling
Number of subjects: 50
Study 35732279 — intervention group
Group type: EXPERIMENTAL
Intervention: FH01
Number of subjects: 41
Study 35732279 — intervention group
Group type: COMPARATOR
Intervention: TT6m
Number of subjects: 41
Study 35732279 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FH01 and TT6m
Number of subjects: 41
Study 32706184 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine‐derived dermal collagen matrix (test site)
Number of subjects: 20
Study 32706184 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (control site)
Number of subjects: 20
Study 32706184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study 32706184 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine‐derived dermal collagen matrix
Number of subjects: 20
Study 35916880 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (eicosapentaenoic and docosahexaenoic acids)
Number of subjects: 436
Study 35916880 — intervention group
Group type: COMPARATOR
Intervention: Placebo (refined olive oil)
Number of subjects: 436
Study 34288070 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-trimester routine ultrasound
Number of subjects: 1275
Study 35970518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg
Number of subjects: 10355
Study 35970518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/violanterol (FF/VI) 100/25 μg
Number of subjects: 10355
Study 35970518 — intervention group
Group type: COMPARATOR
Intervention: UMEC/VI 62.5/25 μg
Number of subjects: 10355
Study 35970518 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 10355
Study 34727465 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Dexamethasone (DXM)
Number of subjects: 45
Study 34727465 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DXM or placebo)
Number of subjects: 45
Study 33734138 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPA-REG OUTCOME trial population
Number of subjects: 8389
Study 32062847 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon self-reported chemoprophylaxis practices
Number of subjects: 66
Study 32062847 — intervention group
Group type: EXPERIMENTAL
Intervention: Administered chemoprophylaxis
Number of subjects: 66
Study 32062847 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative VTE dosing
Number of subjects: 66
Study 33977571 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable membrane (RES)
Number of subjects: 27
Study 33977571 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-resorbable membrane (N-RES)
Number of subjects: 27
Study 32332670 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy at a wavelength of 808 nm, administered twice per week for a total of 12 sessions.
Number of subjects: 0
Study 32332670 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (simulated laser therapy), administered twice per week for a total of 12 sessions.
Number of subjects: 0
Study 34450674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (USG) technique
Number of subjects: 100
Study 34450674 — intervention group
Group type: COMPARATOR
Intervention: Standard single-wall puncture technique (Control)
Number of subjects: 100
Study 35684041 — intervention group
Group type: EXPERIMENTAL
Intervention: Red orange extract (100 mg/day)
Number of subjects: 110
Study 33400435 — intervention group
Group type: EXPERIMENTAL
Intervention: ShotBlocker (n = 47)
Number of subjects: 94
Study 33400435 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 47)
Number of subjects: 94
Study 35166034 — intervention group
Group type: EXPERIMENTAL
Intervention: PENS (10-Hz percutaneous electrical current stimulation)
Number of subjects: 20
Study 35166034 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (same puncture method with no electric stimulation)
Number of subjects: 20
Study 32897461 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 46
Study 32897461 — intervention group
Group type: COMPARATOR
Intervention: Video-based training
Number of subjects: 46
Study 32897461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (In-person and Video-based)
Number of subjects: 46
Study 35657581 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-292 SDD tablet under fed conditions
Number of subjects: 24
Study 35657581 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-292 SDD tablet after multiple doses of omeprazole (40 mg)
Number of subjects: 24
Study 35657581 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-292 SDD formulation (100–300 mg)
Number of subjects: 24
Study 35657581 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-292 under all conditions
Number of subjects: 24
Study 35657581 — intervention group
Group type: COMPARATOR
Intervention: CC-292 under fed vs fasted conditions
Number of subjects: 24
Study 34078380 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated, patient-directed cancer genetics services delivery model
Number of subjects: 2780
Study 34078380 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard of care cancer genetics services delivery model
Number of subjects: 2780
Study 33328269 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg praliciguat
Number of subjects: 156
Study 33328269 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg praliciguat
Number of subjects: 156
Study 33328269 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled praliciguat
Number of subjects: 156
Study 33328269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 35998952 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (MT)
Number of subjects: 64
Study 35998952 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical haematoma evacuation (HE)
Number of subjects: 64
Study 33451591 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1800-2400 mg/d)
Number of subjects: 31
Study 33451591 — intervention group
Group type: COMPARATOR
Intervention: Active comparator (ondansetron 24-32 mg/d or metoclopramide 45-60 mg/d)
Number of subjects: 31
Study 32758179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer group
Number of subjects: 2000
Study 32758179 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (general population)
Number of subjects: 2000
Study 33879709 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitored walking (SM)
Number of subjects: 42
Study 33879709 — intervention group
Group type: COMPARATOR
Intervention: Supervised walking (SU)
Number of subjects: 42
Study 33004730 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Clotrimazole (antifungal)
Number of subjects: 20
Study 33004730 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Number of subjects: 20
Study 33004730 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline with LASER
Number of subjects: 20
Study 33004730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Hypochlorite
Number of subjects: 20
Study 35579708 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-commercial REDCap platform accessed via smartphone
Number of subjects: 0
Study 33963971 — intervention group
Group type: COMPARATOR
Intervention: Single intravenous ascending doses of apitegromab (1, 3, 10, 20, 30 mg/kg)
Number of subjects: 0
Study 33963971 — intervention group
Group type: COMPARATOR
Intervention: Multiple intravenous ascending doses of apitegromab (10, 20, 30 mg/kg)
Number of subjects: 0
Study 33963971 — intervention group
Group type: EXPERIMENTAL
Intervention: Single and multiple doses of apitegromab
Number of subjects: 0
Study 33963971 — intervention group
Group type: COMPARATOR
Intervention: Apitegromab
Number of subjects: 0
Study 33176409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided continuous lumbar plexus block (LPB) with 0.5% ropivacaine (15 mL)
Number of subjects: 0
Study 33176409 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural anesthesia (CEA) with 0.5% ropivacaine (15 mL)
Number of subjects: 0
Study 36268563 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies employed during the study
Number of subjects: 0
Study 36268563 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximizing recruiter availability, developing a responsive communication approach, demonstrating respect for facility procedures and operations, ensuring peak preparedness
Number of subjects: 0
Study 33051215 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 1% and cyclopentolate 0.2% (treatment A)
Number of subjects: 17
Study 33051215 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine 0.5% and cyclopentolate 0.1% (treatment B)
Number of subjects: 17
Study 33051215 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 17
Study 33072067 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-IRG signature in the training cohort
Number of subjects: 464
Study 33072067 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-IRG signature
Number of subjects: 464
Study 33072067 — intervention group
Group type: EXPERIMENTAL
Intervention: Naive B cells, resting memory CD4 T cells, follicular helper T cells, and M2 macrophages
Number of subjects: 464
Study 33072067 — intervention group
Group type: COMPARATOR
Intervention: High-risk cohort
Number of subjects: 464
Study 34817543 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-led surveillance
Number of subjects: 100
Study 34817543 — intervention group
Group type: COMPARATOR
Intervention: Clinician-led surveillance
Number of subjects: 100
Study 34112640 — intervention group
Group type: EXPERIMENTAL
Intervention: Norwegian (n=64)
Number of subjects: 130
Study 34112640 — intervention group
Group type: COMPARATOR
Intervention: English (n=66)
Number of subjects: 130
Study 32633020 — intervention group
Group type: EXPERIMENTAL
Intervention: Greenlight laser vapo-enucleation of the prostate (GL.PVEP)
Number of subjects: 182
Study 32633020 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation of the prostate (HoLEP)
Number of subjects: 182
Study 32633020 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection in saline (TURIS)
Number of subjects: 182
Study 36008086 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative PENG block
Number of subjects: 164
Study 36008086 — intervention group
Group type: COMPARATOR
Intervention: Systemic analgesia alone
Number of subjects: 164
Study 34794998 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred labels (PCL)
Number of subjects: 121
Study 34794998 — intervention group
Group type: COMPARATOR
Intervention: Standard labels
Number of subjects: 121
Study 34794998 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred labels (PCL) in low health literacy participants
Number of subjects: 121
Study 34794998 — intervention group
Group type: COMPARATOR
Intervention: Standard labels in low health literacy participants
Number of subjects: 121
Study 34794998 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred labels (PCL) in low Rapid Estimate of Adult Literacy in Medicine scores
Number of subjects: 121
Study 34794998 — intervention group
Group type: COMPARATOR
Intervention: Standard labels in low Rapid Estimate of Adult Literacy in Medicine scores
Number of subjects: 121
Study 35662679 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery rescripting focused on the feared outcome of the behavioral experiment
Number of subjects: 60
Study 35662679 — intervention group
Group type: COMPARATOR
Intervention: No imagery rescripting (control group)
Number of subjects: 60
Study 32455002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cashew nut seed flour (daily intake for 24 weeks)
Number of subjects: 30
Study 32455002 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study 33853492 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussed treatment goals with doctors (450 respondents, 38.9%)
Number of subjects: 1156
Study 33853492 — intervention group
Group type: COMPARATOR
Intervention: Not discussed treatment goals (287 respondents, 24.8%)
Number of subjects: 1156
Study 33853492 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological agents
Number of subjects: 1156
Study 33853492 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-RANKL antibodies
Number of subjects: 1156
Study 33079955 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-term pregnancies (PlGF)
Number of subjects: 426
Study 33079955 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-term pregnancies (sFlt-1)
Number of subjects: 426
Study 33079955 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-term pregnancies (sFlt-1/PlGF ratio)
Number of subjects: 426
Study 33079955 — intervention group
Group type: EXPERIMENTAL
Intervention: PlGF below the 5th percentile
Number of subjects: 426
Study 33079955 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt-1/PlGF ratio above the 95th percentile
Number of subjects: 426
Study 34311206 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic workplace intervention (12 months with employment specialist)
Number of subjects: 91
Study 34311206 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic workplace attendance during training (Phase 1)
Number of subjects: 91
Study 34311206 — intervention group
Group type: EXPERIMENTAL
Intervention: Opiate- and cocaine-negative urine samples while seeking employment
Number of subjects: 91
Study 34311206 — intervention group
Group type: EXPERIMENTAL
Intervention: Unemployment status at study intake
Number of subjects: 91
Study 34410195 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic informed consent (IC)
Number of subjects: 501
Study 34410195 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face informed consent (IC)
Number of subjects: 501
Study 34215499 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive intravenous hydration (20 ml/kg bolus followed by 3 ml/kg/hr)
Number of subjects: 44
Study 34215499 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous hydration (10 ml/kg bolus followed by 1.5 ml/kg/hr)
Number of subjects: 44
Study 34215499 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive intravenous hydration in obese patients
Number of subjects: 44
Study 34215499 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous hydration in obese patients
Number of subjects: 44
Study 32970730 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 52
Study 32970730 — intervention group
Group type: COMPARATOR
Intervention: Community health services
Number of subjects: 52
Study 35770993 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-kHz spinal cord stimulation (SCS)
Number of subjects: 0
Study 34464522 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-based self-help program
Number of subjects: 402
Study 34464522 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 402
Study 34101004 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected high-protein low-carbohydrate diet for 24 weeks
Number of subjects: 28
Study 32558773 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial emptying fraction (LAEF) measured by cardiac CT
Number of subjects: 92
Study 32558773 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial minimal volume (LAmin)
Number of subjects: 92
Study 32558773 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LAEF and LAmin volume
Number of subjects: 92
Study 32558773 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive LAEF
Number of subjects: 92
Study 36082969 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 391
Study 36082969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 32642847 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D vision
Number of subjects: 40
Study 32642847 — intervention group
Group type: COMPARATOR
Intervention: 2D vision
Number of subjects: 40
Study 32468956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus etoposide and platinum (EP)
Number of subjects: 453
Study 32468956 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus etoposide and platinum (EP)
Number of subjects: 453
Study 35440501 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 46
Study 35440501 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg/day
Number of subjects: 46
Study 35440501 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin and Eplerenone combination
Number of subjects: 46
Study 35440501 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone
Number of subjects: 46
Study 34133509 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (titrated from 20 mg/kg/day or 1,000 mg/day up to 60 mg/kg/day or 3,000 mg/day)
Number of subjects: 114
Study 34133509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 32811460 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity Prevention Group (OPG) - anticipatory guidance on responsive feeding and care practices, with six home visits by a peer educator.
Number of subjects: 430
Study 32811460 — intervention group
Group type: COMPARATOR
Intervention: Injury Prevention Group (IPG) - anticipatory guidance on child safety, with partners only completing study assessments, also receiving six home visits by a peer educator.
Number of subjects: 430
Study 35232232 — intervention group
Group type: EXPERIMENTAL
Intervention: Scientific messaging endorsing the vaccine
Number of subjects: 2037
Study 35232232 — intervention group
Group type: COMPARATOR
Intervention: Partisan messaging endorsing the vaccine
Number of subjects: 2037
Study 32291547 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored expander (KLS Martin®)
Number of subjects: 24
Study 32291547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-borne expander (Hyrax®)
Number of subjects: 24
Study 35775864 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive (N-BCA + OCA; Iceberg-glue®)
Number of subjects: 12
Study 35775864 — intervention group
Group type: COMPARATOR
Intervention: Surgical sutures (0/5 nylon sutures)
Number of subjects: 12
Study 34538401 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive trial design evaluating multiple agents in RCC
Number of subjects: 0
Study 34538401 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration between academia and industry for trial design
Number of subjects: 0
Study 34971796 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with LCS navigation (n = 200)
Number of subjects: 300
Study 34971796 — intervention group
Group type: COMPARATOR
Intervention: Usual care without LCS navigation (n = 100)
Number of subjects: 300
Study 34535071 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 K SNP chip
Number of subjects: 250
Study 36093704 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutritional supplementation (1g fish oil with 500mg DHA, 150mg EPA; 22mg carotenoids; 15mg vitamin E)
Number of subjects: 77
Study 32305122 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation
Number of subjects: 0
Study 32305122 — intervention group
Group type: COMPARATOR
Intervention: Mechanochemical ablation
Number of subjects: 0
Study 34283183 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab (450 mg for body weight of 40‐<60 kg, 600 mg for 60‐80 kg, and 750 mg for >80 kg; n=227)
Number of subjects: 454
Study 34283183 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=227)
Number of subjects: 454
Study 34283183 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 454
Study 34283183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study 33444205 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity (FI) prevalence
Number of subjects: 612
Study 33444205 — intervention group
Group type: EXPERIMENTAL
Intervention: No formal education
Number of subjects: 612
Study 33444205 — intervention group
Group type: EXPERIMENTAL
Intervention: No income-generating activities
Number of subjects: 612
Study 33444205 — intervention group
Group type: EXPERIMENTAL
Intervention: No home gardening practice
Number of subjects: 612
Study 33444205 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use by husbands
Number of subjects: 612
Study 33444205 — intervention group
Group type: EXPERIMENTAL
Intervention: Low minimum dietary diversity score
Number of subjects: 612
Study 33444205 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than three frequencies of meals
Number of subjects: 612
Study 33444205 — intervention group
Group type: EXPERIMENTAL
Intervention: Three meals only per day
Number of subjects: 612
Study 34406244 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation (100 Hz, 200 μs)
Number of subjects: 23
Study 34406244 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 23
Study 35724467 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (60 mg, Day 1 to Day 8)
Number of subjects: 144
Study 35724467 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylactic treatment)
Number of subjects: 144
Study 35724467 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 144
Study 35724467 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 144